REVIEW article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1641618
Nanotechnology-Driven Synergy in Cardio-Oncology: Enhancing 1 Tumor Suppression and Reducing Cardiotoxicity
Provisionally accepted
Luyao Ma1Xiaomei Liu2Shengwei Gao2
Bowen Zhang1Shengjie Kong1Yanfen Li2Ruihua Wang2Meifeng Li2Xinyu Mao2
YU HONG LI1Yang Luo2Liang Li2
Chunxiao Lv2*
Yuhong Huang2*- 1Tianjin University of Traditional Chinese Medicine, Tianjin, China
- 2Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract: The integration of nanotechnology into oncology has profoundly reshaped 18 cancer treatment, enabling drug delivery systems with remarkable precision, 19 enhancing antitumor efficacy, and simultaneously addressing major challenges such 20 as cardiotoxicity, one of the most prevalent and serious adverse effects of 21 conventional chemotherapy. This review systematically examines the dual role of 22 nanotechnology, highlighting its capacity to enhance the therapeutic effectiveness of 23 anticancer treatments while concurrently mitigating cardiotoxic side effects. The 24 discussion centers on a broad spectrum of nanocarrier platforms, such as 25 liposome-based, polymeric nanocarriers, and inorganic nanocarriers organized 26 according to their structural features and therapeutic benefits, thereby enabling a 27 systematic comparison with conventional drug delivery strategies. By improving drug 28 bioavailability, enabling controlled release, and achieving precise tumor-specific 29 targeting, these nanocarrier systems enhance antitumor efficacy while concurrently 30 reducing collateral damage to healthy tissues. Moreover, recent preclinical and 31 clinical studies were summarized to demonstrate substantial advances in this 32 interdisciplinary field, while also identifying persistent challenges that remain to be 33 addressed. Finally, the review explores future directions, with particular emphasis on 34 the integration of artificial intelligence to optimize nanocarrier design and the promise 35 of personalized nanomedicine in transforming cancer care. Overall, this work 36 provides a critical foundation for advancing next-generation, patient-tailored cancer 37 therapies.
Keywords: Cardio-oncology, Nanotechnology, cancer therapy, chemotherapy, Synergy
Received: 05 Jun 2025; Accepted: 09 Sep 2025.
Copyright: © 2025 Ma, Liu, Gao, Zhang, Kong, Li, Wang, Li, Mao, LI, Luo, Li, Lv and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Chunxiao Lv, Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
Yuhong Huang, Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.